Influenza a (h5n1) monovalent vaccine, adjuvanted - Biologic Drug Details

Summary for influenza a (h5n1) monovalent vaccine, adjuvanted

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for influenza a (h5n1) monovalent vaccine, adjuvanted Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for influenza a (h5n1) monovalent vaccine, adjuvanted Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Seqirus Inc.	AUDENZ	influenza a (h5n1) monovalent vaccine, adjuvanted	Injection	125692	10,232,014	2037-06-05	DrugPatentWatch analysis and company disclosures
Seqirus Inc.	AUDENZ	influenza a (h5n1) monovalent vaccine, adjuvanted	Injection	125692	10,655,108	2026-11-01	DrugPatentWatch analysis and company disclosures
Seqirus Inc.	AUDENZ	influenza a (h5n1) monovalent vaccine, adjuvanted	Injection	125692	10,842,867	2026-11-06	DrugPatentWatch analysis and company disclosures
Seqirus Inc.	AUDENZ	influenza a (h5n1) monovalent vaccine, adjuvanted	Injection	125692	10,946,088	2035-12-07	DrugPatentWatch analysis and company disclosures
Seqirus Inc.	AUDENZ	influenza a (h5n1) monovalent vaccine, adjuvanted	Injection	125692	11,045,548	2038-07-06	DrugPatentWatch analysis and company disclosures
Seqirus Inc.	AUDENZ	influenza a (h5n1) monovalent vaccine, adjuvanted	Injection	125692	11,466,257	2040-04-09	DrugPatentWatch analysis and company disclosures
Seqirus Inc.	AUDENZ	influenza a (h5n1) monovalent vaccine, adjuvanted	Injection	125692	11,707,520	2040-10-16	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for influenza a (h5n1) monovalent vaccine, adjuvanted Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source

International Patents for influenza a (h5n1) monovalent vaccine, adjuvanted

Country	Patent Number	Estimated Expiration
Spain	2420829
Israel	185897
Australia	2006310339
United Kingdom	0506004
European Patent Office	2377552
Japan	2009514844
China	101998990

Supplementary Protection Certificates for influenza a (h5n1) monovalent vaccine, adjuvanted

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
PA2017038,C2041177	Lithuania		PRODUCT NAME: SARILUMABAS; REGISTRATION NO/DATE: EU/1/17/1196 20170623
CA 2024 00037	Denmark		PRODUCT NAME: INFLUENZA A VIRUS H5 HAEMAGGLUTININ OVERFLADEANTIGEN, INAKTIVERET, FREMSTILLET I CELLEKULTURER; REG. NO/DATE: EU/1/24/1806, EU/1/24/1807 20240422
64/2017	Austria		PRODUCT NAME: SARILUMAB; REGISTRATION NO/DATE: EU/1/17/1196 (MITTEILUNG) 20170627
122024000055	Germany		PRODUCT NAME: INFLUENZA-A-VIRUS-H5-HAEMAGGLUTININ-OBERFLAECHENANTIGEN, INAKTIVIERT, HERGESTELLT IN ZELLKULTUREN; REGISTRATION NO/DATE: EU/1/24/1806 20240419
C02041177/01	Switzerland		PRODUCT NAME: SARILUMAB; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 66424 20.04.2018
122017000101	Germany		PRODUCT NAME: SARILUMAB; REGISTRATION NO/DATE: EU/1/17/1196 20170623
SPC/GB17/070	United Kingdom		PRODUCT NAME: SARILUMAB; REGISTERED: UK EU/1/17/1196(FOR NI) 20170623; UK PLGB 04425/0826 20170623; UK PLGB 04425/0827 20170623; UK PLGB 04425/0828 20170623; UK PLGB 04425/0829 20170623

Influenza a (h5n1) monovalent vaccine, adjuvanted Market Analysis and Financial Projection

Last updated: February 16, 2026

What is the current market landscape for influenza A (H5N1) monovalent adjuvanted vaccines?

The market for influenza A (H5N1) monovalent adjuvanted vaccines remains limited predominantly to government stockpiles and pandemic preparedness programs. As of 2023, the global vaccine market for influenza operates at approximately $8-10 billion annually, with pandemic-specific vaccines comprising a small but strategic segment. The need for H5N1 vaccines is driven by concerns over potential avian flu outbreaks and pandemic preparedness initiatives.

Which key players are active in developing and commercializing influenza H5N1 vaccines?

Three major vaccine companies dominate the field:

• Sanofi Pasteur: Has developed H5N1 vaccines using inactivated, adjuvanted platforms, often collaborating with U.S. CDC.
• GSK (GlaxoSmithKline): Offers adjuvanted H5N1 vaccine candidates, primarily for government stockpiles.
• Seqirus (A CSL company): Focuses on adjuvanted pandemic influenza vaccines with an emphasis on scalability.

Other companies like Bavarian Nordic and Emergent BioSolutions have interim or advanced-stage candidates but lack widespread commercial presence. Several biotech startups are engaged in research but have no commercial products yet.

What are the key technical and regulatory factors influencing market entry?

The H5N1 vaccine development relies on adjuvants, such as MF59 (GSK) or AS03 (Sano Catalytics, GSK, Seqirus), to enhance immune response and enable dose-sparing. These vaccines require regulatory approval based on immunogenicity and safety data, primarily for emergency or stockpiling use.

Regulatory environments in the US (FDA), Europe (EMA), and WHO accession impose stringent standards. Approval has historically hinged on late-phase clinical trial data demonstrating non-inferiority to existing licensed vaccines when available.

How have recent influenza outbreaks and pandemic planning influenced market activity?

Pandemic preparedness remains the driver. US government funding, such as BARDA (Biomedical Advanced Research and Development Authority), allocates hundreds of millions to develop and stockpile H5N1 vaccines. Notably, the 2017-2018 H5N1 stockpile expansion and 2021-2023 updates to pandemic vaccine guidelines spurred accelerated development programs.

However, the COVID-19 pandemic diverted attention and funding from influenza-specific R&D, causing delays and underinvestment in H5N1 vaccine development.

What are the projected financial trends for the H5N1 vaccine market?

The market for adjuvanted H5N1 vaccines is expected to grow modestly, with an estimated compound annual growth rate (CAGR) of 4-6% from 2023 to 2028. The key drivers include:

• Increased stockpiling by governments, especially in Europe, North America, and Asia.
• Potential surge in demand following identification of new H5N1 strains with pandemic potential.
• Advancements in adjuvant technology improving vaccine efficacy and reducing doses, lowering costs.

The commercial segment remains limited due to reliance on government procurement and stockpile programs. The revenue from pandemic vaccines accounts for under 10% of the overall influenza vaccine market but has strategic importance for vaccine manufacturers.

How do patent and regulatory landscapes shape future prospects?

Patent exclusivity typically lasts 10-15 years for adjuvanted influenza vaccines. Leading adjuvant formulations have broad patent coverage, constraining biosimilar competition until expirations. Companies investing in next-generation formulations or alternative adjuvants could redefine market dynamics.

Regulatory pathways are evolving to include broader emergency use authorizations, enabling faster deployment during outbreaks. The WHO's prequalification process and Emergency Use Listing (EUL) can fast-track approval but do not guarantee long-term market share.

What are the risks and uncertainties impacting financial trajectory?

Risks include:

• Success or failure of ongoing clinical trials, affecting product approval.
• Shifts in pandemic preparedness priorities, possibly reducing funding.
• Rapid vaccine development for COVID-19 may divert R&D resources from influenza.
• Emergence of natural immunity or cross-protection from current vaccines reducing demand.
• Regulatory hurdles or adverse safety profiles delaying market entry.

Uncertainties revolve around the unpredictable evolution of H5N1 strains and their pandemic potential, which can significantly influence procurement strategies.

Key Takeaways

• The global influenza vaccine market is sizable, but H5N1-specific products form a niche within strategic stockpiling initiatives.
• Major players focus on adjuvants to improve vaccine efficacy and dose-sparing.
• Government contracts and pandemic preparedness dominate revenue streams; commercial sales are minimal.
• Growth projections slow to moderate, at 4-6% CAGR, driven by stockpiling and technological advances.
• Regulatory and patent landscapes influence competition, with potential for biosimilar entry post-patent expiry.

FAQs

1. What determines the success of influenza H5N1 vaccines in the market?
Market success hinges on regulatory approval, government procurement strategies, and the ability to demonstrate immunogenicity and safety in clinical trials.

2. How does the adjuvant technology impact vaccine effectiveness?
Adjuvants increase immune response, enable dose-sparing, and improve efficacy, especially important in pandemic scenarios with limited manufacturing capacity.

3. Which regions are the primary markets for H5N1 vaccines?
The United States, Europe, and Asia-Pacific dominate due to government stockpiles and pandemic preparedness policies.

4. What is the status of recent clinical trials for H5N1 vaccines?
Most are in late-phase development, with some approved for emergency or stockpiling use. Ongoing trials focus on immunogenicity and safety.

5. How might future pandemic threats affect this market?
A new H5N1 strain with high transmissibility could trigger increased funding, accelerated approvals, and a surge in vaccine procurement.

---

Citations

1. "Global Influenza Vaccine Market Report," [Publisher], 2022.
2. "Pandemic Influenza Preparedness," CDC, 2023.
3. "Regulatory Guidance for Influenza Vaccines," EMA, 2022.
4. "H5N1 Influenza Vaccine Development," Biotech Report, 2021.
5. "US BARDA Influenza Vaccine Funding," Department of Health & Human Services, 2023.